about
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesBiosimilars: potential implications for cliniciansThe changing landscape of biosimilars in rheumatologyG-CSF and GM-CSF in NeutropeniaReview article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesRegulatory considerations in oncologic biosimilar drug developmentWhat do oncologists need to know about biosimilar products?Biosimilar: what it is notClinical considerations for biosimilar antibodies.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary?Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.CT-P13: design, development, and place in therapyThe approval process for biosimilar erythropoiesis-stimulating agentsUpdate on the safety and bioequivalence of biosimilars - focus on enoxaparin.Biosimilars: Implications for health-system pharmacists.Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.Biosimilars 101: considerations for U.S. oncologists in clinical practiceEpoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Regulatory and clinical considerations for biosimilar oncology drugsBiosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs.A practical guide about biosimilar data for health care providers treating inflammatory diseasesComparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility.Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysisClinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilars: how similar?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationDrift, evolution, and divergence in biologics and biosimilars manufacturing.New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.Biosimilars advancements: Moving on to the future.LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Biosimilar regulation in the EU.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
P2860
Q26738325-347480D1-3BCE-4199-B973-D126905DEF5DQ26744332-4AAAD6B5-D7C6-48B3-9AF7-7EF17110B30FQ26766515-9798F677-BBED-4134-A888-8B5580C1A6C2Q26800954-C34D0D2D-8526-4A11-8E09-F20C34A7F737Q27013577-2E8E1497-BF1B-4A0F-83DC-C877FE309665Q27027947-4D4646E7-BBD6-43BA-8A49-5C0050C3D999Q28071687-A40CC5AE-6F99-4007-AA00-7B7E869D1406Q28080880-514BD144-E913-4F2A-819D-D4482CF3235DQ30377239-515F6A92-9192-4A2F-A205-367D90D28C2AQ30397234-E2BDC98F-BA0B-48C1-A83A-C0F0FB19D276Q30594813-940233F5-735C-41DA-922B-18EC959D7332Q30902172-B6CBF8DB-A8B3-45A5-B0BA-2507702586A2Q33621041-5C325308-4376-444F-A894-A6B6615FCC3FQ33803728-2A07F593-92DC-4A8B-BDBE-53BB81F073EAQ34124734-17D9B6DA-6167-4779-A90F-75C26F9D418BQ34352446-7F79D51F-C7FF-4D53-AF47-4D4B6DB867A1Q34372394-2C483F32-F69B-44AD-AC67-6CF2E586774BQ34909445-7622CB9C-2D35-4B80-B51A-BA4EDEB25F50Q35000438-7EA3F0D3-956F-4098-9AD9-FC80398A4E9BQ35162053-33FFAFFB-DD91-4FD8-AC93-B2709129F1B7Q35505833-4C5579D0-410B-46F0-9D20-A7715508A7B2Q35835005-CDEDD91F-6BF0-4EB0-A59C-E36015B26AA6Q36284094-5B5573AA-4FC4-4FA0-9533-D7D332A32D88Q36303459-87B94314-9E91-47EF-A846-FD5802AC3ED7Q36901212-01681BA7-F9FD-444B-AEC7-D1348576BE6AQ37496465-1A88E4BA-AF17-437E-8055-944D7A20CCF8Q37599251-2514C5CF-A60B-4A00-ABE3-2876081348B6Q38082542-FBB8B0BE-CB4F-4906-9067-E198E75D0719Q38125609-61F55E1A-34F0-4ECB-9DD9-C4EF869525A1Q38151938-6A75E619-99B8-4398-B8AF-96D36CBBAFDAQ38186025-4A348D51-D482-4111-ADBD-BA29D01D44C5Q38190917-F13F3501-565F-44AD-8001-C72056468EC7Q38300338-C9D87ABE-5721-4E6F-B7F7-0F90F5E7B920Q38364577-E8E55370-30DC-4DF5-B7F2-7F8D5F10F71AQ38376297-3F4CBC9B-7BE7-4104-BA45-44598BC977BFQ38432853-A91FF0D4-0501-4816-95D8-2E8EB02D48F6Q38473460-9CB374CA-FBF3-4BAE-8339-A6FED5EE9CF5Q38556990-F30EC94C-BB51-4AE7-A768-9DE993CECC17Q38570723-CA602EA4-14A6-4CE1-BA8D-AEE7F070D9F6Q38586029-B04ED3F6-F54B-4537-BAF8-22C59DDFCDE0
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biosimilars: what clinicians should know.
@en
type
label
Biosimilars: what clinicians should know.
@en
prefLabel
Biosimilars: what clinicians should know.
@en
P2093
P1433
P1476
Biosimilars: what clinicians should know.
@en
P2093
Alexandre Moreau
Camille Vleminckx
Christian K Schneider
Esa Heinonen
Falk Ehmann
Gabriele Reichmann
Gopalan Narayanan
Hans-Karl Heim
Iordanis Gravanis
Karen De Smet
P304
P356
10.1182/BLOOD-2012-04-425744
P407
P577
2012-10-23T00:00:00Z